In this issue

Issue 104 • March 2021

For nearly 40 years, generic drug manufacturers have benefitted from a regulatory system that allows generic drugs to be approved for non-patented indications. This practise – known as skinny labelling – enables drugmakers to enter the market before the brand-name drug’s patent expires, just so long as the generic is not marketed for the same indication as the patent.

Under this system, the generics market has flourished. However, the glory days of skinny labelling may be about to come to an end thanks to an ongoing legal case between GlaxoSmithKline and Teva.

As part of the case, the US federal circuit ruled that a generic pharma company could be at risk of patent infringement based on skinny labelling as generics may still be prescribed for off-label indications – including indications still covered by patent law – if the drug has been promoted as equal to its branded counterpart. But what does this mean for the future of generics? We find out.

Elsewhere in this issue, we take a look at the legacy of the HeLa cell line and the woman behind them, Henrietta Lacks, chart the rise of antibody-drug conjugates, and examine the overlooked GI symptoms of Covid-19.

All this and more in this latest issue of Pharma Technology Magazine.

Eloise Mclennan, editor

Go to article: Home | Getting the skinny on generics labellingGo to article: In this issueGo to article: ContentsGo to article: HOF Sonderanlagenbau Company Insight Go to article: HOF SonderanlagenbauGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: The Solubility companyGo to article: The Solubility Company Insight Go to article: CommentGo to article: Market access of orphan designated therapies at riskGo to article: Lodo Therapeutics’ AI-driven natural drug discovery platformGo to article: Concert Pharmaceuticals discontinues schizophrenia drug after trial failureGo to article: Medical cannabis in Europe: a compelling opportunityGo to article: Exploring the pharma deals outlook in 2021Go to article: In DepthGo to article: Skinny labelling of generics: the beginning of the end for this practice?Go to article: Charting the choppy history of ‘magic bullet’ antibody-drug conjugates Go to article: How a sleeping drug awakened a patient with akinetic mutismGo to article: Breast cancer research: addressing the pre-menopausal problemGo to article: Beyond the lung: treating the GI symptoms of Covid-19Go to article: Immortal cells and informed consent: the legacy of Henrietta LacksGo to article: How radiopharmaceuticals are helping fight cancer with Fusion Go to article: Competition heats up as new HIV prevention drug shows promise Go to article: BaxterGo to article: ACG WorldwideGo to article: In DataGo to article: Inside the dealGo to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article:  Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue